blinatumomab availability in India Archives

November 10, 2025

Blincyto is a targeted immunotherapy approved worldwide to treat certain B-cell Acute Lymphoblastic Leukemia (ALL). The incidence of this disease is approximately 1-2 out of 1,00,000 persons. The adult patients suffering from ALL range from 7.3% to 57.8% whereas ALL in children accounts for 19% of childhood cancers in India by 2021.

Mechanism of action

Blincyto works by the concept of BiTE (Bispecific T-Cell Engager) therapy, in which CD19 surface antigens on B cells are targeted. This enables tracking and attacking the malignant cells by engaging T cells (a type of white blood cell that functions in destroying the cells considered enemies). When the T cells are brought in proximity to the cancer cells, these T cells release toxins and induce cancer cell death (apoptosis). Currently, the BiTE therapy is being investigated for its usage in different types of cancers to benefit patients on a larger scale.

Indications

Blincyto is indicated in the treatment of adults and children aged one month and older with:

CD19-positive B-cell precursor (immature B cell in bone marrow that shows the CD19 marker on its surface) Acute Lymphoblastic Leukaemia (ALL) in first or second complete recovery, along with Minimal Residual Disease (MRD), either greater than or equal to 0.1%.
CD19-positive B-cell precursor Acute Lymphoblastic Leukaemia (ALL) recurrence or refractory type.
CD19-positive B-cell Philadelphia chromosome-negative B-cell precursor Acute Lymphoblastic Leukaemia (ALL) in the consolidation phase of multiphase chemotherapy.

Side-effects

The most common side effects in patients taking Blincyto are high temperature, infusion-related reactions, headache, infection, musculoskeletal pain, low neutrophil count, low Red Blood Cell count, low thrombocyte count, and diarrhoea.

Warnings and precautions

Monitor the patients for infections
Monitor if the patient shows the symptoms of Pancreatitis
Follow the instructions as given by the manufacturer for preparation (including admixing) and administration
Avoid operating heavy or potentially dangerous machinery
Make sure to use preservative-free saline for children weighing less than 22 kg.

Ordering guide

Blincyto is available as an injection form of 35mcg in a single-dose vial. The blinatumomab availability in India is not authorized , but we help patients to import it in case of their critical need when the doctor advises the patient to buy blincyto India or to import it. We have simplified the ordering process in a step-by-step manner.

1) Order for a Blincyto medicine

You can request a Blincyto on the website and send all the medical history of the patient with a valid prescription for a diagnosed condition.

2) Submission of mandatory Form No. 12

Our team guides you in filing the Form No. 12. Submit a valid prescription from a Registered Medical Practitioner (RMD).

3) Confirmation of the documents

We confirm the documents by verifying the prescription given by a registered healthcare worker, and also the personal ID documents from the patient.

4) Blincyto import

Once the government authorities grant permission from the Drugs Controller General (India), we commence with the importation process.

5) Genuineness of the medicine

Our assigned team makes a note of all the worldwide suppliers and makes the best economic choice.

6) Packaging and distribution of the medicine

Our transport team ensures packaging, labeling, and quality and delivery of the product within the stipulated time.

The blinatumomab price in India is not constant, but we guarantee to provide the medicines at a cost-effective price meeting the international pharmaceutical norms, since it involves legal import channels.

Trust 24/7QualityMeds to access the medicines to patients in medical need with absolute transparency. Our dedicated team is here to manage everything, right from the import to delivery, so that you focus on what matters the most.

by 24/7QualityMeds

September 29, 2025

Blincyto is a prescription medicine with the active ingredient blinatumomab (API). It belongs to the class of monoclonal antibodies and is categorized under bispecific T-cell engagers (BiTEs). This advanced immunotherapy drug is approved by the US FDA for the treatment of patients with B-cell precursor acute lymphoblastic leukemia (ALL). Blincyto is available in vials containing 38.5 mcg and 35 mcg of lyophilized powder.

The drug works by engaging and activating T-cells, enabling them to target and destroy CD19-positive B-cells, including malignant leukemia cells. By forming a synapse between T-cells and tumor cells, it triggers the release of cytolytic proteins, cytokines, and promotes T-cell proliferation, ultimately leading to the destruction of leukemia cells.

Blincyto (Blinatumomab) is manufactured using CHO (Chinese hamster ovary) cell lines and represents one of the most innovative approaches in modern hematology.

Blincyto (blinatumomab) is a breakthrough immunotherapy option for patients suffering from acute lymphoblastic leukemia (ALL). While the drug is not yet registered in India, it is legally accessible via import blinatumomab India programs. Patients can safely buy blinatumomab in India through authorized suppliers with proper medical prescription and regulatory support.

For updated details on blinatumomab availability India and assistance in securing the best Blincyto price in India, patients and caregivers are encouraged to connect with licensed sourcing experts.

Medical Uses of Blinatumomab

Blincyto (blinatumomab) is indicated for the treatment of:

CD19-positive B-cell precursor ALL in adult and pediatric patients (≥1 month old) in first or second complete remission with minimal residual disease (MRD ≥0.1%).
Relapsed or refractory CD19-positive B-cell precursor ALL in both adults and children.
Philadelphia chromosome-negative CD19-positive B-cell precursor ALL in the consolidation phase of multiphase chemotherapy.

Blincyto infusion is prepared by mixing the powder with a sterile liquid. It is administered as an intravenous (IV) infusion by a trained healthcare provider in a hospital, clinic, or at home under supervision.

Pricing:

Blincyto 38.5 mcg Injection in India is usually prescribed by hematologists and oncologists, especially for patients who are candidates for bone marrow transplant (BMT). However, Blincyto is not registered in India and is not readily available through local pharmacies or standard distribution networks.

Indian patients can buy Blincyto in India through the Named Patient Import License route, which allows access to unregistered drugs for personal medical use. The cost of Blincyto in India may vary, and patients are advised to seek expert guidance for reliable sourcing.

Blincyto is manufactured and promoted by Amgen and may also be referred to by its generic name, blinatumomab. Since it is an imported drug, the Blincyto price in India depends on international supplier costs, shipping, and authorization processes.

Patients, physicians, and hospitals may consult licensed importers to buy blinatumomab in India at the best available price. For updated pricing information and purchase support, contact:

Import Steps:

Since Blincyto is not commercially registered in India, patients must use the legal Named Patient Import Program to obtain it. The process involves:

Doctor’s Prescription – A treating hematologist/oncologist must prescribe Blincyto for the patient.
Application for Import – Patients or caregivers apply for a Named Patient Import License through India’s regulatory authority.
Authorization and Procurement – A licensed supplier arranges for the legal import of Blincyto from authorized international sources.
Delivery – The medicine is shipped securely to major Indian cities such as Delhi, Mumbai, Bangalore, Kolkata, Hyderabad, Chennai, Pune, Ahmedabad, and others.

This ensures that import of blinatumomab India is safe, legal, and compliant with health regulations.

Access Information:

As Blincyto is not marketed in India through regular distribution, patients can access it only via special import channels. Licensed providers and import facilitators ensure that blinatumomab availability in India is maintained for patients in need.

Blincyto (blinatumomab) can be made available not only across major Indian cities but also in overseas regions like the UK, UAE, Turkey, and Egypt. Patients who require urgent access can benefit from expert assistance in handling documentation, sourcing, and customs clearance.

With proper medical prescription and regulatory approvals, patients can buy Blincyto injection in India legally and access the therapy without unnecessary delays.

To buy Blincyto in India or know the latest Blincyto price, visit 247qualitymeds.com for trusted guidance and secure ordering.

Blincyto (Blinatumomab) in India: Mechanism, Safety Profile & Ordering Guide